Trial Profile

A Partially Randomized, Sequential Cohort, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Subcutaneous Ravulizumab Coadministered With rHuPH20 in Healthy Adult Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hyaluronidase (Primary) ; Ravulizumab (Primary)
Indications Acute kidney injury; Dermatomyositis; Haemolytic uraemic syndrome; IgA nephropathy; Lupus nephritis; Myasthenia gravis; Neuromyelitis optica; Paroxysmal nocturnal haemoglobinuria; Thrombotic microangiopathies
Focus Adverse reactions; Pharmacokinetics
Sponsors Alexion AstraZeneca Rare Disease

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com